IL304697A - Use of a gambit inhibitor alone or in combination with fedratinib or ruxolitinib for the treatment of hematological malignancies such as myelofibrosis - Google Patents

Use of a gambit inhibitor alone or in combination with fedratinib or ruxolitinib for the treatment of hematological malignancies such as myelofibrosis

Info

Publication number
IL304697A
IL304697A IL304697A IL30469723A IL304697A IL 304697 A IL304697 A IL 304697A IL 304697 A IL304697 A IL 304697A IL 30469723 A IL30469723 A IL 30469723A IL 304697 A IL304697 A IL 304697A
Authority
IL
Israel
Prior art keywords
fedratinib
ruxolitinib
myelofibrosis
treating
combination
Prior art date
Application number
IL304697A
Other languages
English (en)
Hebrew (he)
Inventor
Ida Aronchik
Valencia Roxxana Valeria Beltran
Anton Maria Soraya Carrancio
Henry H Chang
Shodeinde Coker
Sharmila Das
Ellen Hope Filvaroff
Marhuenda Carla Guarinos
Bishoy Hanna
Yu Liu
Zariana Nikolova
Oriana Esposito
Original Assignee
Impact Biomedicines Inc
Ida Aronchik
Valencia Roxxana Valeria Beltran
Anton Maria Soraya Carrancio
Henry H Chang
Shodeinde Coker
Sharmila Das
Ellen Hope Filvaroff
Marhuenda Carla Guarinos
Bishoy Hanna
Yu Liu
Zariana Nikolova
Oriana Esposito
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Impact Biomedicines Inc, Ida Aronchik, Valencia Roxxana Valeria Beltran, Anton Maria Soraya Carrancio, Henry H Chang, Shodeinde Coker, Sharmila Das, Ellen Hope Filvaroff, Marhuenda Carla Guarinos, Bishoy Hanna, Yu Liu, Zariana Nikolova, Oriana Esposito filed Critical Impact Biomedicines Inc
Publication of IL304697A publication Critical patent/IL304697A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Disintegrating Or Milling (AREA)
IL304697A 2021-02-25 2023-07-24 Use of a gambit inhibitor alone or in combination with fedratinib or ruxolitinib for the treatment of hematological malignancies such as myelofibrosis IL304697A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP21382163 2021-02-25
US202163232866P 2021-08-13 2021-08-13
US202263297098P 2022-01-06 2022-01-06
PCT/US2022/017678 WO2022182857A1 (en) 2021-02-25 2022-02-24 Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis

Publications (1)

Publication Number Publication Date
IL304697A true IL304697A (en) 2023-09-01

Family

ID=80786345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL304697A IL304697A (en) 2021-02-25 2023-07-24 Use of a gambit inhibitor alone or in combination with fedratinib or ruxolitinib for the treatment of hematological malignancies such as myelofibrosis

Country Status (12)

Country Link
US (2) US12357621B2 (cg-RX-API-DMAC7.html)
EP (1) EP4297750A1 (cg-RX-API-DMAC7.html)
JP (1) JP2024507938A (cg-RX-API-DMAC7.html)
KR (1) KR20230148208A (cg-RX-API-DMAC7.html)
AU (1) AU2022227673B2 (cg-RX-API-DMAC7.html)
CA (1) CA3206708A1 (cg-RX-API-DMAC7.html)
CL (1) CL2023002497A1 (cg-RX-API-DMAC7.html)
IL (1) IL304697A (cg-RX-API-DMAC7.html)
MX (1) MX2023009858A (cg-RX-API-DMAC7.html)
TW (1) TW202302095A (cg-RX-API-DMAC7.html)
WO (1) WO2022182857A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA202307538B (cg-RX-API-DMAC7.html)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010363329A1 (en) * 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
EP4351560A4 (en) 2021-06-08 2025-06-04 The Regents of the University of California ANTI-CANCER COMPOUNDS
KR20260019479A (ko) 2023-05-04 2026-02-10 레볼루션 메디슨즈, 인크. Ras 관련 질환 또는 장애를 위한 병용 요법
CN121889155A (zh) 2023-08-07 2026-04-17 锐新医药公司 用于治疗ras蛋白相关疾病或病症的rmc-6291
AU2024360465A1 (en) 2023-10-12 2026-04-09 Revolution Medicines, Inc. Macrocyclic ras inhibitors
WO2025171296A1 (en) 2024-02-09 2025-08-14 Revolution Medicines, Inc. Ras inhibitors
WO2025240847A1 (en) 2024-05-17 2025-11-20 Revolution Medicines, Inc. Ras inhibitors
US20250375445A1 (en) 2024-06-07 2025-12-11 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2025265060A1 (en) 2024-06-21 2025-12-26 Revolution Medicines, Inc. Therapeutic compositions and methods for managing treatment-related effects
WO2026006747A1 (en) 2024-06-28 2026-01-02 Revolution Medicines, Inc. Ras inhibitors
WO2026015790A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015801A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015796A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Methods of treating a ras related disease or disorder
WO2026015825A1 (en) 2024-07-12 2026-01-15 Revolution Medicines, Inc. Use of ras inhibitor for treating pancreatic cancer
WO2026050446A1 (en) 2024-08-29 2026-03-05 Revolution Medicines, Inc. Ras inhibitors
WO2026072904A2 (en) 2024-09-26 2026-04-02 Revolution Medicines, Inc. Compositions and methods for treating lung cancer
WO2026090116A2 (en) 2024-10-21 2026-04-30 Revolution Medicines, Inc. Ras inhibitors
US20260108528A1 (en) 2024-10-22 2026-04-23 Revolution Medicines, Inc. Methods of treating a ras protein-related disease or disorder
WO2026090245A1 (en) 2024-10-22 2026-04-30 Revolution Medicines, Inc. Use of ras inhibitors for treating cancer
WO2026106912A1 (en) 2024-11-12 2026-05-21 Revolution Medicines, Inc. Ras inhibitors
WO2026112260A1 (en) 2024-11-21 2026-05-28 Revolution Medicines, Inc. Ras inhibitors
WO2026122764A2 (en) 2024-12-06 2026-06-11 Revolution Medicines, Inc. Ras inhibitors
WO2026128688A2 (en) 2024-12-13 2026-06-18 Revolution Medicines, Inc. Ras inhibitors
WO2026161839A1 (en) 2025-01-27 2026-07-30 Revolution Medicines, Inc. Ras inhibitors

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2007053452A1 (en) 2005-11-01 2007-05-10 Targegen, Inc. Bi-aryl meta-pyrimidine inhibitors of kinases
HUE028588T2 (hu) 2005-12-13 2016-12-28 Incyte Holdings Corp Heteroaril-szubsztituált pirrolo[2,3-b]piridinek és pirrolo[2,3-b]pirimidinek mint Janus-kináz inhibitorok
EP2740731B1 (en) 2007-06-13 2016-03-23 Incyte Holdings Corporation Crystalline salts of the janus kinase inhibitor (r)-3-(4-(7h-pyrrolo[2,3-d]pyrimidin-4-yl)-1h-pyrazol-1-yl)-3-cyclopentylpropanenitrile
AU2010363329A1 (en) 2010-11-07 2013-05-09 Targegen, Inc. Compositions and methods for treating myelofibrosis
US9458156B2 (en) 2014-12-23 2016-10-04 Bristol-Myers Squibb Company Tricyclic compounds as anticancer agents
EA201990240A1 (ru) * 2013-12-24 2019-06-28 Бристол-Маерс Сквибб Компани Новые трициклические соединения в качестве противораковых средств
MA43037A (fr) * 2015-10-02 2018-08-08 Dana Farber Cancer Inst Inc Polythérapie par inhibiteurs de bromodomaine et blocage de point de contrôle
WO2020051572A1 (en) * 2018-09-07 2020-03-12 H. Lee Moffitt Cancer Center And Research Institute, Inc. Brd4-jak2 inhibitors
MY209349A (en) 2018-09-25 2025-07-03 Impact Biomedicines Inc Methods of treating myeloproliferative disorders
DK3908281T3 (da) * 2019-01-09 2024-10-21 Celgene Corp Antiproliferative forbindelser og sekundære aktive midler til anvendelse til behandling af multipelt myelom
US12559463B2 (en) 2019-02-12 2026-02-24 Impact Biomedicines Inc. Crystalline forms of a JAK2 inhibitor
HRP20251457T1 (hr) * 2020-06-03 2026-01-02 Incyte Corporation Kombinacija ruksolitiniba s incb057643 za uporabu u liječenju mijeloproliferativnih neoplazmi

Also Published As

Publication number Publication date
TW202302095A (zh) 2023-01-16
US12357621B2 (en) 2025-07-15
CA3206708A1 (en) 2022-09-01
AU2022227673A9 (en) 2024-09-19
JP2024507938A (ja) 2024-02-21
WO2022182857A1 (en) 2022-09-01
KR20230148208A (ko) 2023-10-24
AU2022227673B2 (en) 2026-06-04
MX2023009858A (es) 2023-09-12
ZA202307538B (en) 2026-01-28
EP4297750A1 (en) 2024-01-03
CL2023002497A1 (es) 2024-01-12
AU2022227673A1 (en) 2023-08-17
US20250367174A1 (en) 2025-12-04
US20220265617A1 (en) 2022-08-25

Similar Documents

Publication Publication Date Title
IL261717B (en) Combinations of lsd1 inhibitors for the treatment of hematological malignancies
CA198078S (en) Deck box
ZA201800366B (en) Methods of treating hematological malignancy using nanoparticle mtor inhibitor combination therapy
IL236050B (en) Methods for preserving starch in pulp and controlling calcium deposition and/or peeling
SMT202300236T1 (it) Composti e composizioni per il trattamento di disturbi ematologici
IL235963A0 (en) Mutant selectivity and combinations of a phosphoinositide 3-kinase inhibitor compound and chemotherapeutic agents for cancer treatment
IL214132A0 (en) Combinations of phosphoinositide 3-kinase inhibitor compounds and chemotherapeutic agents for the treatment of hematopoietic malignancies
SI2662416T1 (sl) Obdelava kalcijev karbonat vsebujočih snovi za povečanje nalaganja polnila v papirju
IL315025A (en) Compounds and preparations for the treatment of hematological disorders
UA99869C2 (ru) Ручной привод для переключателя отводов обмоток ступенчатых трансформаторов
ZA201207550B (en) Fe(iii) complex compounds for the treatment and prophylaxis of iron deficiency symptoms and iron deficiency anemias
ZA201308335B (en) Process for treating microfibrillated cellulose and microfibrillated cellulose treated according to the process
GB202305122D0 (en) Methods for treating metastasis with cathepsin c inhibitors
SG11201707281QA (en) Use of mk2 inhibitor peptide-containing compositions for treating non-small cell lung cancer with same
HK40096705A (en) Use of a bet inhibitor alone or in combination with fedratinib or ruxolitinib for treating a hematological malignancy such as myelofibrosis
IL284856A (en) DBAIT molecule in combination with a kinase inhibitor for cancer treatment
EP2384115A4 (en) METHODS AND COMPOSITIONS FOR TREATING HEMATOLOGICAL MALIGNANT TUMORS
IL212413A0 (en) Inhibitors of mitosis for increasing apoptosis in therapy
IL306046A (en) A preparation for use in the treatment of disorders related to MHC-1
AU2019257493A1 (en) Method for preventing and/or treating chronic traumatic encephalopathy-I
IL309002A (en) Compounds useful in the treatment or prevention of a PRMT5-mediated disorder
PL2691376T3 (pl) Związki kompleksowe żelaza(III) do leczenia i profilaktyki objawów niedoboru żelaza i anemii uwarunkowanych niedoborem żelaza
ZA201002576B (en) Novel composition for treating the side effects of anticancer treatments
IL312532A (en) BET inhibitor for the treatment of glioblastoma
PL4146225T3 (pl) Związki metylotioniniowe do zastosowania w leczeniu hipoksemii